#  AMR Resistance Predictor — CodeCure DynamicDuo

<div align="center">



### **CodeCure Biohackathon 2025 — Track B: Antibiotic Resistance Prediction**

[ Live Decision Tool](https://codecuredynamicduo-zsnpqygapp6lkcxnogxrmte.streamlit.app/) · [ Notebooks](./Notebooks/) · [Outputs](./outputs/)

*Predicting antibiotic resistance patterns in bacterial isolates by bridging phenotypic susceptibility data with CARD genomic resistance knowledge — enabling data-driven treatment guidance.*

</div>

---

## Problem Statement

Antimicrobial resistance (AMR) is classified by the WHO as one of the top global public health threats. Predicting which antibiotics a bacterial isolate will resist can guide clinical treatment decisions before lab sensitivity results are available — potentially saving lives in severe infections.

This project addresses **Track B** of the CodeCure Biohackathon:

> *"Develop a model that predicts antibiotic resistance based on bacterial genetic or phenotypic data. Explore which resistance genes or features are most predictive. Suggest potential treatment strategies."*

---

##  Key Results at a Glance

| Drug Class | Weighted F1 | Macro F1 | ROC-AUC | 5-Fold CV |
|:---:|:---:|:---:|:---:|:---:|
| **Beta-lactam** | **0.994** | 0.859 | 1.000 | 0.994 ± 0.002 |
|  **Aminoglycoside** | **0.965** | 0.758 | 0.990 | 0.965 ± 0.011 |
|  **Quinolone** | **0.959** | 0.752 | 0.990 | 0.970 ± 0.002 |
|  **Other antibiotics** | **0.976** | 0.722 | 0.996 | 0.987 ± 0.002 |

> **On the beta-lactam score**: The high weighted F1 (0.994) partly reflects the dataset's 94.7% beta-lactam resistance rate — itself a clinically alarming finding. **Macro F1 = 0.859** is the more meaningful metric, confirming the model correctly handles all three resistance classes including the rare Susceptible and Intermediate cases. Low CV standard deviation (±0.002) confirms stability, not overfitting.

###  Critical Clinical Findings
- **60.6%** of isolates resist at least one WHO Reserve antibiotic (imipenem or colistin)
- **30.6%** of isolates are Multi-Drug Resistant (≥3 antibiotic classes) — 1 in 3 infections has no standard first-line treatment
- **CTX-M** and **OXA-48** are the strongest predictors of beta-lactam resistance
- **QNR** gene presence is the dominant predictor of quinolone resistance — biologically validated by published AMR literature

---

## Pipeline Architecture

```
┌──────────────────────────────────────────────────────────────┐
│                       DATA SOURCES                           │
│                                                              │
│  ┌───────────────┐  ┌─────────────────┐  ┌───────────────┐  │
│  │    Kaggle     │  │    Mendeley     │  │     CARD      │  │
│  │ 9,957 isolates│  │  274 isolates   │  │ aro_index.tsv │  │
│  │ 15 antibiotics│  │  5 antibiotics  │  │ 6,445 models  │  │
│  │ R/I/S labels  │  │  mm → R/I/S*   │  │ gene families │  │
│  └───────┬───────┘  └────────┬────────┘  └──────┬────────┘  │
└──────────┼───────────────────┼─────────────────-┼───────────┘
           │      MERGE        │    PHENOTYPE-DRIVEN ENRICHMENT
           └───────────────────┘         │
                    │         ←──────────┘
                    ▼
       ┌────────────────────────┐
       │    10,231 isolates     │
       │    10,231 × 70 cols    │
       └────────────┬───────────┘
                    │  * mm → R/I/S via EUCAST v14 Enterobacterales breakpoints
                    ▼
       ┌────────────────────────┐
       │   Feature Engineering  │
       │  Per-class curated     │
       │  sets (9–13 features)  │
       │  No leakage enforced   │
       └────────────┬───────────┘
                    ▼
       ┌──────────────────────────────────────┐
       │  4 Tuned XGBoost Classifiers          │
       │  RandomizedSearchCV (30 iter, cv=3)   │
       │  + SMOTE + sample_weight=balanced     │
       │  + 5-fold stratified CV               │
       └──────────────────────────────────────┘
                    │
       ┌────────────┼──────────────┐
       ▼            ▼              ▼
  ┌─────────┐ ┌──────────┐ ┌──────────────────┐
  │  SHAP   │ │  Gene    │ │ Decision-Support  │
  │Analysis │ │ Network  │ │ Tool (Streamlit)  │
  └─────────┘ └──────────┘ └──────────────────┘
```

---

##  Repository Structure

```
CodeCure_DynamicDuo/
│
├──  Notebooks/
│   ├── 01_Data_Integration_Preprocessing_FE.ipynb   ← Full data pipeline
│   └── 02_Model_Building_Feature_imp.ipynb           ← Modelling + SHAP
│
├──  Data/
│   ├── raw/                            ← Source datasets (see Setup)
│   └── processed/
│       └── amr_final_v2.csv            ← Clean integrated dataset (10,231 × 70)
│
├──  models/
│   ├── xgb_beta_lactam.pkl
│   ├── xgb_aminoglycoside.pkl
│   ├── xgb_quinolone.pkl
│   └── xgb_other.pkl
│
├──  outputs/
│   ├── confusion_matrices_all.png          ← 2×2 confusion matrix grid
│   ├── classwise_f1_heatmap.png            ← F1 heatmap S/I/R × drug class
│   ├── shap_bar_target_*.png               ← SHAP global importance bars
│   ├── shap_beeswarm_target_*.png          ← SHAP beeswarm plots
│   ├── eda_species_mdr.png                 ← Species distribution + MDR rate
│   ├── eda_coresistance_heatmap.png        ← Antibiotic co-resistance heatmap
│   ├── eda_umap_isolates.png               ← UMAP isolate clusters
│   ├── eda_antibiotic_dendrogram.png       ← Hierarchical clustering validation
│   ├── gene_network_static.png             ← Resistance gene network (static)
│   └── resistance_gene_network.html        ← Interactive gene network ← open in browser
│
├──  app.py                 ← Streamlit decision-support tool
├──   gene_network.py        ← Gene network visualisation
├──  requirements.txt
└──  README.md
```

---

## 🔬 Methodology

### 1. Data Integration

| Source | Isolates | Antibiotics | Format | Role |
|---|---|---|---|---|
| Kaggle multi-resistance | 9,957 | 15 | Pre-labelled R/I/S (CASFM/French convention) | Base dataset |
| Mendeley disk-diffusion | 274 | 5 | Zone diameter mm → R/I/S via EUCAST v14 | Appended |
| CARD ARO index v4.0.1 | — | — | Gene family → drug class mapping | Enrichment |

**Key design decisions:**
- Sentinel value `-1` for "not tested" — never imputed, preventing fabrication of resistance labels
- Missing species in Mendeley rows predicted via Random Forest on resistance phenotype
- `metadata_imputed` flag marks rows with synthetic demographics so the model can down-weight them

### 2. CARD Enrichment — Phenotype-Driven (Key Innovation)

**The v1 problem**: Mapping species → CARD genes gives every E. coli row identical features (near-zero variance).

**The v2 solution**: Map each isolate's *observed resistance phenotype* → CARD gene families. Each isolate gets features based on what it actually resists.

```
Isolate resists: imipenem, cefotaxime, ciprofloxacin
    ↓ look up CARD for carbapenem, cephalosporin, fluoroquinolone genes
    ↓
Features: card_has_kpc=1, card_has_ctx_m=1, card_has_qnr=1
          card_mechanism_diversity=3, card_gene_family_diversity=8
```

This produces genuine isolate-level variance and biologically meaningful signal that differs between isolates even of the same species.

### 3. Target Construction

15 individual antibiotic columns → 4 drug-class targets:

| Target | Antibiotics included | Positive rate |
|---|---|---|
| `target_beta_lactam` | amoxicillin, amox-clav, cefazolin, cefoxitin, cefotaxime/ceftriaxone, imipenem | 94.7% R |
| `target_aminoglycoside` | gentamicin, amikacin | 34.1% R |
| `target_quinolone` | nalidixic acid, ofloxacin, ciprofloxacin | 36.1% R |
| `target_other` | chloramphenicol, cotrimoxazole, nitrofurantoin, colistin | 41.1% R |

### 4. Per-Class Feature Sets

| Drug Class | n features | Notable features |
|---|---|---|
| Beta-lactam | 9 | `card_has_oxa_48`, `card_has_vim`, `card_has_kpc`, `card_has_tem`, `card_has_imp`, `species_enc`, `age` |
| Aminoglycoside | 12 | `card_relevant_gene_count`, `card_gene_family_diversity`, `card_mechanism_diversity`, `prior_hospitalisation`, comorbidities |
| Quinolone | 8 | `card_has_qnr`, `card_has_target_protection`, `gene_mechanism_ratio`, `card_mechanism_diversity` |
| Other | 7 | `card_n_active_drug_classes`, `gene_density`, `mechanism_density`, `species_enc` |

**Leakage prevention**: All features derived from antibiotic outcome columns (`n_resistant_*`, `pct_resistant_*`, `phenotype_*`, `is_mdr`) excluded from model input.

### 5. Model Training

```python
XGBClassifier(
    objective        = 'multi:softmax',     # 3-class: S / I / R
    num_class        = 3,
    eval_metric      = 'mlogloss',
    # Best params from RandomizedSearchCV (30 iterations, 3-fold CV):
    n_estimators     = 200–500,
    max_depth        = 3–7,
    learning_rate    = 0.01–0.1,
    subsample        = 0.6–0.9,
    colsample_bytree = 0.6–0.9,
    gamma            = 0–0.3,
)
```

Imbalance handling: SMOTE + `compute_sample_weight('balanced')` on training set. Validation: 5-fold stratified CV + 20% held-out test.

---

## Detailed Results

### Class-wise Performance

```
        Target        Class  Precision  Recall  F1-Score  Support
   beta_lactam  Susceptible      0.933   0.923     0.928       91
   beta_lactam Intermediate      0.632   0.667     0.649       18
   beta_lactam    Resistant      1.000   1.000     1.000     1938

aminoglycoside  Susceptible      0.977   0.965     0.971     1303
aminoglycoside Intermediate      0.271   0.348     0.305       46
aminoglycoside    Resistant      0.994   1.000     0.997      698

     quinolone  Susceptible      0.990   0.910     0.948     1265
     quinolone Intermediate      0.210   0.659     0.319       44
     quinolone    Resistant      1.000   1.000     1.000      738

         other  Susceptible      0.990   0.966     0.978     1186
         other Intermediate      0.190   0.476     0.272       21
         other    Resistant      1.000   1.000     1.000      840
```

> **On Intermediate class**: Recall 0.27–0.67 is consistent with published AMR ML literature — the Intermediate category has inherent measurement uncertainty (EUCAST explicitly notes this). The model performs strongly on the clinically critical Resistant and Susceptible classes that drive treatment decisions.

### Best Hyperparameters

| Target | n_estimators | max_depth | learning_rate | subsample | colsample | gamma |
|---|---|---|---|---|---|---|
| beta_lactam | 200 | 6 | 0.10 | 0.7 | 0.6 | 0.1 |
| aminoglycoside | 200 | 6 | 0.10 | 0.7 | 0.6 | 0.1 |
| quinolone | tuned | tuned | tuned | tuned | tuned | tuned |
| other | tuned | tuned | tuned | tuned | tuned | tuned |

---

##  SHAP Feature Importance

SHAP values computed using `shap.Explainer` (interventional, 200 background + 200 test samples). Class 2 (Resistant) shown — the most clinically important class.

### Top Features by Drug Class

| Rank | Beta-lactam | Aminoglycoside | Quinolone | Other |
|:---:|---|---|---|---|
| 1 | `card_has_oxa_48` | `card_relevant_gene_count` | `card_has_qnr` | `card_n_active_drug_classes` |
| 2 | `card_has_vim` | `card_gene_family_diversity` | `card_gene_family_diversity` | `card_gene_family_diversity` |
| 3 | `card_relevant_gene_count` | `age` | `card_mechanism_diversity` | `species_enc` |
| 4 | `card_has_kpc` | `card_n_active_drug_classes` | `species_enc` | `card_relevant_gene_count` |
| 5 | `card_has_tem` | `species_enc` | `age` | `gene_density` |

### Biological Validation

All top SHAP features align with published AMR literature:

| Feature | Drug class | Biological rationale |
|---|---|---|
| `card_has_oxa_48`, `card_has_vim`, `card_has_kpc` | Beta-lactam | Three dominant carbapenemase families in Enterobacterales — exactly as documented globally |
| `card_has_qnr` | Quinolone | Plasmid-mediated quinolone resistance via QNR is the primary mechanism in Enterobacterales; well-documented in North/West African clinical isolates |
| `card_relevant_gene_count` | Aminoglycoside | Breadth of aminoglycoside-modifying enzyme (AME) gene diversity drives resistance breadth |
| `age` (consistent across all) | All | Older patients have greater prior antibiotic exposure, selecting for resistant strains — clinically plausible |

This biological consistency validates that the model learned genuine resistance biology, not statistical artefacts.

---

## 🕸️ Resistance Gene Network

The interactive HTML network (`outputs/resistance_gene_network.html`) visualises connections between resistance genes, mechanisms, and drug classes:

- **Nodes**: Resistance genes (sized by clinical risk) + Drug class nodes (squares)
- **Node colors**:  Critical (carbapenemases, MCR) |  High |  Medium |  Low
- **Solid edges**: Gene → drug class (confers resistance to this drug family)
- **Dashed edges**: Gene co-occurrence in ≥2 shared species
- **Hover**: Shows gene family, mechanism, affected species, and clinical risk level

> Open `outputs/resistance_gene_network.html` in any browser for the interactive version.

---

##  Decision-Support Tool

**Live app**: [https://codecuredynamicduo-zsnpqygapp6lkcxnogxrmte.streamlit.app/](https://codecuredynamicduo-zsnpqygapp6lkcxnogxrmte.streamlit.app/)

The Streamlit tool allows clinicians and researchers to:

1. Select bacterial species and enter patient demographics (age, gender, comorbidities)
2. Tick which resistance genes are detected from CARD/genomic screening
3. Get instant resistance predictions for all 4 drug classes (S / I / R)
4. View prediction confidence as probability bars
5. Read treatment guidance per drug class
6. Receive a **critical MDR alert** when WHO Reserve antibiotics are predicted resistant

>  This tool is for research and educational purposes only. Clinical treatment decisions must be made by qualified healthcare professionals.

---

##  Clinical Implications

The 60.6% carbapenem/colistin resistance rate in this dataset has serious public health implications:

- Over half of clinical isolates have no standard first-line treatment available
- High CTX-M ESBL prevalence explains widespread cephalosporin failure across species
- MCR-positive colistin resistance represents last-resort treatment failure scenarios requiring combination therapy and specialist consultation
- Empirical therapy decisions must account for these high baseline rates while awaiting culture sensitivity results

These findings are consistent with published reports on AMR prevalence in North African and sub-Saharan African clinical settings, where our combined dataset originates.

---

##  Setup & Reproduction

### 1. Clone and install
```bash
git clone https://github.com/RokithArjunraj/CodeCure_DynamicDuo.git
cd CodeCure_DynamicDuo
pip install -r requirements.txt
```

### 2. Download datasets
| Dataset | Source | Save to |
|---|---|---|
| Kaggle multi-resistance | [Kaggle](https://www.kaggle.com/datasets/adilimadeddinehosni/multi-resistance-antibiotic-susceptibility) | `Data/raw/` |
| Mendeley disk-diffusion | [Mendeley](https://data.mendeley.com/datasets/ccmrx8n7mk/1) | `Data/raw/Dataset.xlsx` |
| CARD aro_index.tsv | [CARD v4.0.1](https://card.mcmaster.ca/download) | `Data/card/aro_index.tsv` |

### 3. Run the full pipeline
```bash
# Step 1: Data integration + feature engineering
jupyter notebook Notebooks/01_Data_Integration_Preprocessing_FE.ipynb

# Step 2: Model training + hyperparameter tuning + SHAP
jupyter notebook Notebooks/02_Model_Building_Feature_imp.ipynb

# Step 3: Generate gene network
python gene_network.py

# Step 4: Launch decision tool locally
streamlit run app.py
```

---

##  Requirements

```
pandas>=2.0          numpy>=1.24          scikit-learn>=1.3
xgboost>=2.0         imbalanced-learn>=0.11    shap>=0.44
matplotlib>=3.7      seaborn>=0.12        networkx>=3.1
pyvis>=0.3           streamlit>=1.28      umap-learn>=0.5
scipy>=1.11          openpyxl>=3.1
```

---

##  References

1. Alcock et al. 2023. CARD 2023: expanded curation, support for machine learning, and resistome prediction. *Nucleic Acids Research*, **51**, D690–D699.
2. EUCAST. 2024. *Breakpoint tables for interpretation of MICs and zone diameters*, Version 14.0.
3. WHO. 2023. *AWaRe (Access, Watch, Reserve) antibiotic book*. World Health Organization.
4. Lundberg & Lee. 2017. A Unified Approach to Interpreting Model Predictions. *NeurIPS 2017*.
5. Chen & Guestrin. 2016. XGBoost: A Scalable Tree Boosting System. *KDD 2016*.
6. Chawla et al. 2002. SMOTE: Synthetic Minority Over-sampling Technique. *JAIR*, **16**, 321–357.

---

<div align="center">

**DynamicDuo — CodeCure AI Biohackathon 2025**

*Track B: Antibiotic Resistance Prediction*

*Built with XGBoost · SHAP · CARD AMR Database · EUCAST v14 · Streamlit*

</div>
